このページの読み込み中にエラーが発生したようです.
当社チームに通知しましたが、問題が続くようでしたらEメールサポートウィジェットを使ってご連絡ください。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBITDA Multiple | 0.3x - 0.3x | 0.3x |
| Selected Fwd EBITDA Multiple | 0.1x - 0.1x | 0.1x |
| Fair Value | $3.88 - $3.84 | $3.86 |
| Upside | 42.7% - 41.0% | 41.8% |
| Benchmarks | Ticker | Full Ticker |
| Ovid Therapeutics Inc. | OVID | NasdaqGS:OVID |
| Syros Pharmaceuticals, Inc. | SYRS | OTCPK:SYRS |
| Caribou Biosciences, Inc. | CRBU | NasdaqGS:CRBU |
| Regen BioPharma, Inc. | RGBP | OTCPK:RGBP |
| Vaxart, Inc. | VXRT | NasdaqCM:VXRT |
| Relay Therapeutics, Inc. | RLAY | NasdaqGM:RLAY |
| - | - | - |
| Select LTM EBITDA Multiple | |||||||
| Benchmark Companies | |||||||
| OVID | SYRS | CRBU | RGBP | VXRT | RLAY | ||
| NasdaqGS:OVID | OTCPK:SYRS | NasdaqGS:CRBU | OTCPK:RGBP | NasdaqCM:VXRT | NasdaqGM:RLAY | ||
| Historical EBITDA Growth | |||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| Latest Twelve Months | -1.3% | 17.1% | -40.6% | NM | 23.1% | -1.6% | |
| Historical EBITDA Profit Margin | |||||||
| 5 Year Average Margin | -9342.5% | -2519.3% | -697.8% | 0.0% | -12267.1% | -8880.0% | |
| Prior Fiscal Year | -14544.1% | -831.0% | -326.4% | NA | -1012.6% | -1464.6% | |
| Latest Fiscal Year | -10207.1% | -1250.5% | -1582.8% | NA | -200.1% | -3799.4% | |
| Latest Twelve Months | -10207.1% | -28544.0% | -1582.8% | NA | -200.1% | -3799.4% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | -23.75x | 7.18x | -13.56x | 5.73x | 2.35x | -27.15x | |
| EV / LTM EBITDA | 0.2x | 0.0x | 0.9x | NA | -1.2x | 0.7x | |
| EV / LTM EBIT | 0.2x | 0.0x | 0.8x | -3.2x | -1.0x | 0.7x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBITDA | -1.2x | 0.1x | 0.9x | ||||
| Historical EV / LTM EBITDA | -26.9x | -2.8x | 0.7x | ||||
| Selected EV / LTM EBITDA | 0.3x | 0.3x | 0.3x | ||||
| (x) LTM EBITDA | (380) | (380) | (380) | ||||
| (=) Implied Enterprise Value | (100) | (106) | (111) | ||||
| (-) Non-shareholder Claims * | 733 | 733 | 733 | ||||
| (=) Equity Value | 633 | 627 | 622 | ||||
| (/) Shares Outstanding | 169.5 | 169.5 | 169.5 | ||||
| Implied Value Range | 3.73 | 3.70 | 3.67 | ||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 3.73 | 3.70 | 3.67 | 2.72 | |||
| Upside / (Downside) | 37.2% | 36.0% | 34.9% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | OVID | SYRS | CRBU | RGBP | VXRT | RLAY | |
| Enterprise Value | (34) | 3 | (145) | 1 | 68 | (272) | |
| (+) Cash & Short Term Investments | 53 | 58 | 210 | 0 | 52 | 781 | |
| (+) Investments & Other | 21 | 0 | 49 | 0 | 0 | 0 | |
| (-) Debt | (15) | (60) | (26) | (1) | (23) | (49) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | (0) | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 25 | 1 | 87 | 1 | 96 | 461 | |
| (/) Shares Outstanding | 71.1 | 26.8 | 93.0 | 10.5 | 227.9 | 169.5 | |
| Implied Stock Price | 0.35 | 0.03 | 0.94 | 0.05 | 0.42 | 2.72 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.35 | 0.03 | 0.94 | 0.05 | 0.42 | 2.72 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |